Showing results (201-210 of 261) with videos related to

Sort By:
Pageof 27
Biomolecular NMR Assignments|June 6, 2022
1H, 13C, and 15N resonance assignments and solution structures of the KH domain of human ribosome binding factor A, mtRbfA, involved in mitochondrial ribosome biogenesisKanako Kuwasako, Sakura Suzuki, Nobukazu Nameki, et al.
Internal Medicine (Tokyo, Japan)|November 2, 2020
Anxiety, Depression, and Resilience of Healthcare Workers in Japan During the Coronavirus Disease 2019 OutbreakNobuyasu Awano, Nene Oyama, Keiko Akiyama, et al.
Respiratory Medicine Case Reports|August 25, 2021
A case of pulmonary sclerosing pneumocytoma diagnosed preoperatively using transbronchial cryobiopsyYutaka Muto, Naoyuki Kuse, Minoru Inomata, et al.
Biochemical and Biophysical Research Communications|March 10, 2012
Structural insights into the dual-targeting mechanism of Nutlin-3Jae-Sun Shin, Ji-Hyang Ha, Fahu He, et al.
Nature Structural & Molecular Biology|August 19, 2014
RBFOX and SUP-12 sandwich a G base to cooperatively regulate tissue-specific splicingKanako Kuwasako, Mari Takahashi, Satoru Unzai, et al.
European Journal of Cancer (Oxford, England : 1990)|July 16, 2015
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911Kazuhiko Yamada, Hiromi Aono, Yukio Hosomi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 5, 2022
Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLCRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.
Journal for Immunotherapy of Cancer|June 29, 2026
Pharmacokinetic variability with pembrolizumab dosage switching and its impact on immune-related adverse events in patients with non-small cell lung cancerRyoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, et al.
European Journal of Cancer (Oxford, England : 1990)|December 22, 2021
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Tatsuya Imabayashi, et al.
The Journal of Biological Chemistry|January 15, 2013
Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathwaysJi-Hyang Ha, Jae-Sun Shin, Mi-Kyung Yoon, et al.
Pageof 27